Loading...
Please wait, while we are loading the content...
Similar Documents
Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Mahnke, Karsten Qian, Yingjie Fondel, Sabine Brück, Jürgen Becker, Christian Enk, Alexander H. |
| Copyright Year | 2005 |
| Abstract | Anti (alpha)-DEC-205 antibodies target to the DEC-205 receptor that mediates antigen presentation to T cells by dendritic cells. To exploit these properties for immunization purposes, we conjugated the melanoma antigen tyrosinase-related protein (TRP)-2 to alphaDEC-205 antibodies and immunized mice with these conjugates together with dendritic cell-activating oligonucleotides (CpG). Upon injection of the melanoma cell line B16, alphaDEC-TRP immunized mice were protected against tumor growth. Even more important for clinical applications, we were able to substantially slow the growth of implanted B16 cells by injection of alphaDEC-TRP2 conjugates into tumor bearing hosts. Approximately 70% of the animals were cured from existing tumors by treatment with alphaDEC conjugates carrying two different melanoma antigens (TRP-2 and gp100). This protection was due to induction of melanoma-specific CD4 and CD8 responses. Thus, these data show that targeting of dendritic cells in situ by the means of antibody-antigen conjugates may be a novel way to induce long-lasting antitumor immunity. |
| File Format | PDF HTM / HTML |
| DOI | 10.1158/0008-5472.CAN-05-0938 |
| Alternate Webpage(s) | http://cancerres.aacrjournals.org/content/canres/65/15/7007.full.pdf |
| PubMed reference number | 16061687 |
| Alternate Webpage(s) | https://doi.org/10.1158/0008-5472.CAN-05-0938 |
| Journal | Medline |
| Volume Number | 65 |
| Issue Number | 15 |
| Journal | Cancer research |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
